ATE318141T1 - Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen - Google Patents

Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen

Info

Publication number
ATE318141T1
ATE318141T1 AT98937635T AT98937635T ATE318141T1 AT E318141 T1 ATE318141 T1 AT E318141T1 AT 98937635 T AT98937635 T AT 98937635T AT 98937635 T AT98937635 T AT 98937635T AT E318141 T1 ATE318141 T1 AT E318141T1
Authority
AT
Austria
Prior art keywords
taurolidine
taurultam
production
medicinal product
preventing metastases
Prior art date
Application number
AT98937635T
Other languages
German (de)
English (en)
Inventor
Rolf Pfirrmann
Original Assignee
Geistlich Soehne Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geistlich Soehne Ag filed Critical Geistlich Soehne Ag
Application granted granted Critical
Publication of ATE318141T1 publication Critical patent/ATE318141T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT98937635T 1997-07-31 1998-07-31 Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen ATE318141T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9716219.2A GB9716219D0 (en) 1997-07-31 1997-07-31 Prevention of metastases

Publications (1)

Publication Number Publication Date
ATE318141T1 true ATE318141T1 (de) 2006-03-15

Family

ID=10816777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98937635T ATE318141T1 (de) 1997-07-31 1998-07-31 Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen

Country Status (7)

Country Link
EP (1) EP1001781B1 (OSRAM)
JP (2) JP2001511463A (OSRAM)
AT (1) ATE318141T1 (OSRAM)
DE (1) DE69833554T2 (OSRAM)
ES (1) ES2255172T3 (OSRAM)
GB (1) GB9716219D0 (OSRAM)
WO (1) WO1999006114A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7132413B1 (en) 1997-07-31 2006-11-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
CA2302720C (en) * 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
CN100519525C (zh) 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
JP2003515558A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療するためのメチロール含有化合物の使用
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
AU779362B2 (en) * 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US6753328B2 (en) * 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
CA2482687C (en) 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
GB9400163D0 (en) * 1994-01-06 1994-03-02 Geistlich Soehne Ag Membrane
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren

Also Published As

Publication number Publication date
EP1001781A2 (en) 2000-05-24
WO1999006114A3 (en) 1999-04-08
GB9716219D0 (en) 1997-10-08
DE69833554D1 (de) 2006-04-27
JP2010215615A (ja) 2010-09-30
WO1999006114A2 (en) 1999-02-11
JP2001511463A (ja) 2001-08-14
EP1001781B1 (en) 2006-02-22
DE69833554T2 (de) 2006-08-10
ES2255172T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
ATE318141T1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen
WO1998016523A3 (en) Selective factor xa inhibitors
WO2000071507A3 (en) INHIBITORS OF FACTOR Xa
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE69736183D1 (de) Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
ZA9710796B (en) Oxyiminopregnanecarbolactones.
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
DK0883405T3 (da) Aminoproteaseinhibitorer
WO1996040743A3 (en) Inhibitors of factor xa
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
SE9600216D0 (sv) Styrning av läkningsprocesser
ATE267597T1 (de) Verwendung von polycyclischen 2-amino-thiazol systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
DE50007381D1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
SE9802209D0 (sv) Novel compounds
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
WO2001014576A3 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE232723T1 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE324111T1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1001781

Country of ref document: EP